Inventor · disambiguated record
Daniel Sylvester
Also filed as: SYLVESTER DANIEL R · SYLVESTER DANIEL ROBERT
8 granted patents·4 pending applications·184 citations·filing 1995–2006
87Inventor score
Files withSMITHKLINE BEECHAM CORP8SMITHKLINE BEECHAM PLC2GLAXOSMITHKLINE LLC1SMITHKLINE BEECHAM CORP AND TH1
Top patents by PatentIndex Score
12 records- 0189US6005091ANucleic acids encoding immunoglobulin domainsSMITHKLINE BEECHAM CORP·Filed 1997·Granted Dec 21, 1999·57 cites·7 claims
- 0283US6391299B1Anti-factor IX/IXa antibodiesSMITHKLINE BEECHAM CORP·Filed 1999·Granted May 21, 2002·33 cites·13 claims
- 0383US5928904ADNA encoding recombinant IL4 antibodies useful in treatment of IL4 mediated disordersSMITHKLINE BEECHAM CORP·Filed 1995·Granted Jul 27, 1999·59 cites·33 claims
- 0478US5914110ARecombinant IL4 antibodies useful in treatment of IL4 mediated disordersSMITHKLINE BEECHAM CORP·Filed 1995·Granted Jun 22, 1999·31 cites·39 claims
- 0562US2005002959A1Recombinant IL4 antibodies useful in treatment of IL4 mediated disordersSMITHKLINE BEECHAM PLC·Filed 2003·Application pending·0 cites
- 0659US7807793B2Recombinant IL4 antibodies useful in treatment of IL4 mediated disordersGLAXOSMITHKLINE LLC·Filed 2006·Granted Oct 5, 2010·0 cites·6 claims
- 0758US2002146411A1Anticoagulant agents useful in treatment of thrombosisSMITHKLINE BEECHAM CORP·Filed 2002·Application pending·0 cites
- 0857US2007003553A1Anticoagulant agents useful in treatment of thrombosisSMITHKLINE BEECHAM CORP AND TH·Filed 2005·Application pending·0 cites
- 0955US2002193575A1Recombinant IL4 antibodies useful in treatment of IL4 mediated disordersSMITHKLINE BEECHAM PLC·Filed 2001·Application pending·0 cites
- 1043US6410688B1Def1SMITHKLINE BEECHAM CORP·Filed 1999·Granted Jun 25, 2002·3 cites·14 claims
- 1132US6448038B1BirA from staphylococcus aureusSMITHKLINE BEECHAM CORP·Filed 1999·Granted Sep 10, 2002·1 cites·15 claims
- 1231US6586578B1DeflSMITHKLINE BEECHAM CORP·Filed 1997·Granted Jul 1, 2003·0 cites·22 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →